Estee Lauder Companies, Inc. (NYSE:EL) shares fell Thursday as investors positioned ahead of the company’s third-quarter earnings report due on Friday.
Estee Lauder Invests In 111SKIN
Separately, the company announced a minority investment in luxury clinical skincare brand 111SKIN, founded by Dr. Yannis Alexandrides. Terms were not disclosed.
The move targets rising demand for science-backed, treatment-inspired skincare. Known for its NAC Y2 technology, 111SKIN offers premium products priced between $50 and $1,000 and sells through luxury retail, e-commerce, and spa channels globally.
The brand generates about 20% of sales from direct-to-consumer channels and has a strong presence in North America, China, Europe, and Asia-Pacific.
Dr. Alexandrides will continue leading the company, while Estee Lauder aims to expand its global reach and strengthen its position in clinical skincare.
Technical Analysis
Estee Lauder Companies is sitting well off its 52-week high of $121.64 and closer to the lower half of its $56.66–$121.64 range, which is consistent with a longer repair phase after a big drawdown.
The stock is trading 1.8% above its 20-day simple moving average (SMA) but 22% below its 100-day SMA, a mix that points to a short-term bounce inside a …
This post was originally published here
